EBOO, short for extracorporeal blood oxygenation and ozonation, is a procedure in which blood is drawn from a vein, passed through a device that exposes it to an oxygen-ozone gas mixture, filtered, and then returned to the body through another vein. It belongs to the broader family of medical ozone therapies but stands apart because it can treat a much larger volume of blood per session than older methods. The procedure remains investigational, and despite growing interest from integrative and alternative medicine clinics, the published evidence base is still thin enough that it warrants careful scrutiny.
How the Procedure Actually Works
EBOO uses a setup that resembles dialysis more than a typical IV drip. Two venous access points are placed, usually one in each arm. Blood flows out of one line, enters a specialized device where it contacts a controlled mix of medical-grade oxygen and ozone gas, passes through a filtration membrane, and returns to the bloodstream through the second line. The extracorporeal circuit means blood is continuously leaving, being treated, and coming back during the session, rather than being drawn into a syringe and reinfused in batches.
Early published work on the technique reported that the apparatus could treat up to about 4,800 ml of blood over the course of a one-hour extracorporeal circulation, using an oxygen-ozone concentration in the range of 0.5 to 1 microgram per milliliter of oxygen. By comparison, the older method known as autohemotherapy (AHT) could only process roughly 250 ml of blood per session. That dramatic difference in volume is the core technical advantage EBOO was designed to offer.1PubMed. Extracorporeal blood oxygenation and ozonation: clinical and biological implications of ozone therapy
The blood’s exposure to ozone is brief. Within seconds of contact, the ozone gas dissolves in plasma and reacts with components already present in the blood. By the time the treated blood returns to the body, the ozone itself is gone. What remains are the chemical byproducts of that reaction, which proponents argue trigger beneficial downstream effects.
The Biochemistry Behind the Buzz
Understanding EBOO requires knowing what ozone actually does when it meets blood. Ozone is a highly reactive molecule. When it dissolves in the watery portion of plasma, it reacts almost instantly with polyunsaturated fatty acids and antioxidant compounds, producing a burst of reactive oxygen species (ROS) and lipid oxidation products (LOPs). Among these byproducts are hydrogen peroxide and protein-bound molecules collectively referred to as modified aldehydes.2PubMed Central. How Does Ozone Act? How and Why Can We Avoid Ozone Toxicity?
The idea behind using these reactions therapeutically is a concept called hormesis: a small, controlled stress that pushes the body to ramp up its own defense systems. At low concentrations, ozone-generated ROS act less like toxins and more like signaling molecules. They trigger cells to activate protective antioxidant pathways, particularly one centered on a protein called Nrf2. When Nrf2 gets switched on, it drives the production of the body’s own antioxidant enzymes, which can persist long after the ozone itself has been consumed.3PubMed Central. The Role of Nrf2 in the Antioxidant Cellular Response to Medical Ozone Exposure Laboratory experiments have confirmed that low ozone concentrations increase both Nrf2 levels and the expression of genes it controls.4PubMed Central. Ozone Activates the Nrf2 Pathway and Improves Preservation of Explanted Adipose Tissue In Vitro
The lipid oxidation products generated by ozone also appear to play a role. These LOPs act as signal transducers in their own right, promoting what researchers call “mitohormetic” processes, meaning they stimulate mitochondria to become more efficient and resilient.5PubMed Central. Mechanisms of Action of Ozone Therapy in Emerging Viral Diseases: Immunomodulatory Effects and Therapeutic Advantages With Reference to SARS-CoV-2 The proposed chain of events, then, is: ozone creates a brief oxidative jolt, the body responds by strengthening its antioxidant and immune defenses, and the patient walks away with elevated protective capacity. Whether this chain works as cleanly in practice as it sounds on paper is where the evidence gets complicated.
What Has Been Studied Clinically
The clinical research specifically on EBOO, as distinct from ozone therapy in general, is limited. One of the few controlled trials compared EBOO to prostacyclin (a standard pharmaceutical treatment) in patients with peripheral artery disease. Patients who received EBOO showed significantly greater improvement in skin lesions compared to the drug-treated group, along with meaningful improvements in pain, itching, leg heaviness, and self-reported well-being. The researchers did not find significant differences in actual blood flow to the lower limbs between the two groups, which is a notable caveat: patients felt and looked better, but their underlying circulation did not measurably change. No side effects or complications were recorded during 210 EBOO treatments in that trial.6PubMed. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease
A recent case report described EBOO used in an 88-year-old patient with chronic anemia, tracking urinary excretion of various toxins before and after treatment. Over a series of sessions, the patient’s measured levels of mycotoxins dropped by about 65%, heavy metals by about 26%, and environmental toxins by roughly 55%.7PubMed Central. Observed Reduction in Urinary Toxin Excretion With Extracorporeal Blood Oxygenation and Ozonation (EBOO) Treatment in an 88-Year-Old With Chronic Anemia: A Case Report These numbers sound impressive, but a case report on a single patient cannot establish that EBOO was the cause of those reductions, and urinary toxin levels can fluctuate for many reasons.
A small retrospective case series of eight patients examined laboratory biomarker changes following EBOO, documenting it as an extracorporeal procedure involving oxygen-ozone exposure and blood filtration.8Journal of Complementary and Alternative Medical Research. Laboratory Biomarker Changes Following Extracorporeal Blood Oxygenation and Ozonation (EBOO): A Retrospective Eight-Patient Case Series Again, the sample size is too small to draw broad conclusions from, but the data contributes to the slow accumulation of preliminary evidence.
Some of the claims made about EBOO draw on research into ozone therapy more broadly, using older delivery methods. For instance, a study of 22 patients who had experienced a heart attack found that ozone autohemotherapy over 15 sessions led to significant decreases in total cholesterol and LDL cholesterol, along with increases in antioxidant enzyme activity in red blood cells.9PubMed. Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy These results are sometimes cited in EBOO marketing, but they used a different delivery method and a very small group. Extrapolating from AHT results to EBOO is a stretch without direct evidence bridging the two.
How EBOO Differs from Other Forms of Ozone Therapy
EBOO is sometimes marketed as the most advanced form of ozone therapy, and the volume difference is real. The foundational published work noted that older autohemotherapy could treat only about 250 ml of blood per session, while EBOO could process nearly 5 liters in the same timeframe.1PubMed. Extracorporeal blood oxygenation and ozonation: clinical and biological implications of ozone therapy In AHT, a small volume of blood is drawn into a syringe, mixed with ozone, and re-injected. In “major autohemotherapy” (MAH), that volume might go up to about 200-250 ml. EBOO’s continuous-flow design bypasses the batch limitation entirely.
Other ozone delivery methods exist that do not involve blood at all: ozone can be applied topically to wounds, insufflated into body cavities, or dissolved in water or oil. EBOO occupies the intensive end of the spectrum, requiring IV access, anticoagulation (typically heparin to keep blood from clotting in the circuit), and specialized equipment. This makes it more invasive than other ozone modalities, more expensive, and harder to find. It also means the safety profile carries additional risks associated with any extracorporeal blood treatment: potential for air embolism, infection at IV sites, and reactions to anticoagulant drugs.
The Evidence Gap
This is where anyone considering EBOO should pay close attention. The researchers who originally developed the technique acknowledged that clinical validation of even simpler ozone therapies had been “largely insufficient,” and that extensive investigation and further clinical trials were needed to validate EBOO.1PubMed. Extracorporeal blood oxygenation and ozonation: clinical and biological implications of ozone therapy That was published nearly two decades ago, and the situation has not changed as dramatically as you might hope. The total body of EBOO-specific literature consists of a handful of case reports, one controlled trial in peripheral artery disease, and a few retrospective chart reviews. There are no large randomized controlled trials, no systematic reviews, and no meta-analyses focused on EBOO.
This gap matters because the mechanistic story is plausible but unproven at scale. The Nrf2 pathway is real, the antioxidant upregulation happens in lab settings, and the hormetic concept is well established in biology. But having a reasonable biological rationale is the starting line for medical treatments, not the finish line. Many interventions with excellent-sounding mechanisms have failed to produce meaningful clinical benefits when subjected to rigorous testing. The jump from “ozone triggers antioxidant enzymes in a petri dish” to “EBOO treats chronic disease in humans” requires evidence that, for now, largely does not exist.
Clinics offering EBOO tend to describe it as helpful for a wide range of conditions, including chronic infections, autoimmune disease, Lyme disease, mold illness, chronic fatigue, and cardiovascular problems. Some of these claims lean on the broader ozone therapy literature, some on the theoretical mechanism, and some appear to be driven more by clinical anecdote than published data. A reader evaluating these claims should ask whether the evidence comes from EBOO specifically or from other ozone modalities, and whether the study involved a control group or just a handful of patients.
Regulatory Standing and Safety
The U.S. Food and Drug Administration has not approved ozone as a medical treatment. The agency has warned against the use of ozone therapy due to its toxic properties and the lack of proven benefits at tolerable exposure levels.10PubMed Central. Neurological Crisis Following Intravenous Ozone Therapy; a Case Report This regulatory stance applies broadly to ozone therapy, including EBOO. In the United States, EBOO is offered at private integrative medicine clinics operating outside of conventional insurance-based healthcare. Patients typically pay out of pocket, and costs can run into the hundreds or thousands of dollars per session depending on the clinic and the number of treatments in a series.
The safety record in published studies appears reasonably clean. The peripheral artery disease trial reported no side effects across 210 sessions, and the original developers described more than 1,200 treatments in 82 patients “without technical or clinical problems.”1PubMed. Extracorporeal blood oxygenation and ozonation: clinical and biological implications of ozone therapy But published case reports, by their nature, tend to come from experienced research centers following strict protocols. What happens in the growing number of private clinics adopting the technology may not mirror those conditions. Adverse events from ozone therapy in general, though uncommon in the literature, have included cases of neurological complications, infections, and embolism, most often linked to improper administration or dangerously high ozone concentrations.
If you are considering EBOO, verifying the credentials of the administering practitioner matters more than it would for many other procedures, precisely because there is no standardized training pathway or certification board. Questions worth asking include what concentration and volume protocol the clinic uses, whether the equipment has been properly maintained and calibrated, and what adverse event monitoring is in place during and after the session.
What a Session Feels Like
From the patient’s perspective, EBOO is somewhat uneventful. You sit in a chair or recline on a treatment bed with IV lines in both arms. Blood visibly flows out one side, through tubing, into the ozone-contact device, and back in through the other arm. Sessions typically last about an hour. The blood passing through the machine often changes color visibly, appearing darker going in and brighter red coming out, which practitioners point to as evidence of improved oxygenation. Skeptics note that blood will always appear redder after contact with oxygen regardless of whether that translates to a therapeutic benefit.
Some patients report feeling energized or clear-headed after a session; others notice little difference. These subjective responses are difficult to separate from placebo effects, especially given that the experience of watching your blood being “cleaned” and returned is psychologically powerful. Most treatment protocols involve a series of sessions rather than a single treatment, ranging from three to ten sessions spaced days or weeks apart, though no standardized protocol exists.
The Detox Framing and Its Limits
A significant portion of EBOO marketing uses the language of “detoxification,” claiming the procedure removes heavy metals, mycotoxins, and environmental chemicals from the blood. The case report of the 88-year-old patient that tracked urinary toxin excretion is the most directly relevant published data supporting this framing, showing reductions in several categories of measured toxins after a treatment series.7PubMed Central. Observed Reduction in Urinary Toxin Excretion With Extracorporeal Blood Oxygenation and Ozonation (EBOO) Treatment in an 88-Year-Old With Chronic Anemia: A Case Report
There are reasons to be cautious about these numbers. A single patient is not a study. Urinary excretion of toxins can vary with hydration, diet, kidney function, and time of day. Without a control group, it is impossible to know whether the same patient would have shown similar changes from the passage of time alone. The filtration component of EBOO may genuinely remove some substances from blood, similar to how dialysis removes waste products, but whether it removes clinically meaningful quantities of toxins that the liver and kidneys were not already handling is an open question.
The “detox” framing also overlaps with a broader pattern in alternative medicine where vague claims about removing unnamed toxins are used to justify a wide range of treatments. When specific toxins are named and measured, as in the case report above, the claim becomes testable. But the leap from “we measured lower mycotoxin levels in urine after treatment” to “EBOO detoxifies your body” glosses over enormous gaps in understanding about what drove the change and whether it mattered for health outcomes.
Who Seeks Out EBOO and Why
The typical person exploring EBOO has often been through conventional medical channels without finding satisfactory answers. Chronic Lyme disease, mold-related illness, long COVID, chronic fatigue, and autoimmune conditions are among the most common reasons patients report seeking out the treatment. These are conditions where mainstream medicine sometimes offers limited relief, and patients understandably look for alternatives. EBOO’s appeal in this context comes partly from its plausible biological mechanism and partly from the sheer drama of the procedure: watching your blood visibly pass through a machine and return feels like something is being done, in a way that swallowing a pill does not.
Practitioners who offer EBOO often combine it with other integrative therapies, including IV nutrient infusions, chelation, and various supplements. This bundling makes it even harder to assess EBOO’s independent contribution, since patients receiving multiple interventions simultaneously cannot know which one (if any) is responsible for improvements they experience. For patients weighing the decision, the honest picture is that EBOO rests on an interesting but unproven biological rationale, extremely limited clinical data, no regulatory approval, and costs that can add up quickly. Those are not reasons to dismiss it entirely, but they are reasons to approach it with open eyes and realistic expectations about what the science currently supports.